Clinical Trial Update: HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating HEC73543 versus salvage chemotherapy in relapsed/refractory FLT3-ITD acute myeloid leukemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• HEC73543 (HEC73543)

Snippet

Sponsor: Sunshine Lake Pharma Co., Ltd. | Conditions: Leukemia, Acute Myeloid (AML) | Phase 3 | Status: RECRUITING